RhLIGHT enhances PDGF-BB and TGF-β production by STAT3 and Smad3 activation in BM-MSCs.

<p>Cells were incubated with 0, 100, and 200 ng/mL rhLIGHT for 72 h at 37°C, and the supernatant was collected. (A) PDGF-BB production, as determined by ELISA assay. (B) TGF-β production, as determined by ELISA assay. (C) Expression of p-STAT3, STAT3, p-smad 3, and smad 3, as determined by western blotting. The membrane was stripped and reprobed with anti-β-actin mAb to confirm equal loading. Data represent the mean ± SEM. Significantly different from the control cells (*); **, <i>P</i> < 0.01; ***, <i>P</i> < 0.001.</p

LIGHT (TNFSF14) Increases the Survival and Proliferation of Human Bone Marrow-Derived Mesenchymal Stem Cells

<div><p>LIGHT (HVEM-L, TNFSF14, or CD258), an entity homologous to <u>l</u>ymphotoxins, with <u>i</u>nducible nature and the ability to compete with herpes simplex virus <u>g</u>lycoprotein D for <u>h</u>erpes virus entry mediator (HVEM)/<u>t</u>umor necrosis factor (TNF)-related 2, is a member of the TNF superfamily. It is expressed as a homotrimer on activated T cells and dendritic cells (DCs), and has three receptors: HVEM, LT-β receptor (LTβR), and decoy receptor 3 (DcR3). So far, three receptors with distinct cellular expression patterns are known to interact with LIGHT. Follicular DCs and stromal cells bind LIGHT through LTβR. We monitored the effects of LIGHT on human bone marrow-derived mesenchymal stem cells (BM-MSCs). At first, we checked the negative and positive differentiation markers of BM-MSCs. And we confirmed the quality of MSCs by staining cells undergoing adipogenesis (Oil Red O staining), chondrogenesis (Alcian blue staining), and osteogenesis (Alizarin red staining). After rhLIGHT treatment, we monitored the count, viability, and proliferation of cells and cell cycle distribution. PDGF and TGFβ production by rhLIGHT was examined by ELISA, and the underlying biological mechanisms were studied by immunoblotting by rhLIGHT treatment. LTβR was constitutively expressed on the surface of human BM-MSCs. Cell number and viability increased after rhLIGHT treatment. BM-MSC proliferation was induced by an increase in the S/G₂/M phase. The expression of not only diverse cyclins such as cyclin B1, D1, D3, and E, but also CDK1 and CDK2, increased, while that of p27 decreased, after rhLIGHT treatment. RhLIGHT-induced PDGF and TGFβ production mediated by STAT3 and Smad3 activation accelerated BM-MSC proliferation. Thus, LIGHT and LTβR interaction increases the survival and proliferation of human BM-MSCs, and therefore, LIGHT might play an important role in stem cell therapy.</p></div

Radotinib induces caspase-3 dependent apoptosis of CD11b⁺ cells differentiated from AML cells.

<p>Kasumi-1 cells were incubated with 0, 1, 5, and 10 μM of radotinib, and BMCs from a patient with AML were stimulated with 0, 1, 10 and 100 μM of radotinib for 72 h. Then the cells were harvested and used for measurements of the mitochondrial membrane potential using Dioc₆(3) dye, intracellular staining for cleaved caspase-3, or studies of the caspase-3 activity in CD11b⁺ cells, as described in Materials and Methods. (A) The percentage of Dioc₆(3)⁺ cells in the total population of CD11b⁺ cells. (B) The number of Dioc₆(3)⁺ cells among CD11b⁺ cells. (C) CD11b⁺cleaved caspase-3⁺ cells among Kasumi-1 cells. (D) CD11b⁺ cleaved caspase-3⁺ cells among BMCs isolated from an AML-3 patient. (E) The expression of Annexin V, CD11b, and cleaved caspase-3 induced by 5 μM radotinib in Kasumi-1 cells was monitored by FlowSight analysis. (F) Caspase-3 activity in CD11b⁺ Kasumi-1 cells. Data represent the mean ± SEM. Statistically significant differences from the DMSO-treated control (*) are denoted as follows. ***: <i>P</i> < 0.001. BF, bright field; cCas-3, cleaved caspase-3.</p

Proposed pathway of LIGHT and LTβR interaction in human BM-MSCs.

<p>LIGHT and LTβR interaction increases the survival and proliferation of human BM-MSCs by activating survival proteins, anti-apoptotic proteins, CDKs, and cyclins. Moreover, LIGHT-induced STAT-3 and smad-3 activation causes PDGF and TGF-β production, and they enhance LIGHT signals in human BM-MSCs. Therefore, LIGHT may play an important role in stem cell therapy, and contribute to MSC modification.</p

HPLC analysis and the structure of radotinib.

<p>(A) Radotinib was analyzed by HPLC as described in the Materials and Methods section. (B) The chemical structure of radotinib.</p

RhLIGHT increases the number of human BM-MSCs.

<p>Cells were incubated with 0, 100, and 200 ng/mL rhLIGHT for 72 h. (A) Images of low density (left panel) and high density (right panel) by BSA-control treatment (0.1% BSA-PBS buffer, upper panel) and rhLIGHT treatment (lower panel) in the BM-MSCs. (B) Dose-dependent effect of rhLIGHT on the number of human BM-MSCs at 72 h. (C) Time-dependent effect of rhLIGHT (200 ng/mL) on the number of human BM-MSCs. Data represent the mean ± SEM. Significantly different from the control cells (*); ***, <i>P</i> < 0.001. BSA, bovine serum albumin.</p

Radotinib regulates several signaling pathways.

<p>Kasumi-1 cells were incubated with 5 μM radotinib for 48 h. Cells were harvested, total RNA was isolated and subjected to microarray analysis, as described in the Materials and Methods. (A) The number of genes in categorized pathways affected by radotinib. (B) The percentage of distribution of radotinib-affected genes in each pathway.</p

RhLIGHT activates various genes associated with TNF and chemokines in human BM-MSCs.

<p>Cells were incubated with 0, 100, and 200 ng/ml rhLIGHT for 48 h. (A) The number of genes in categorized pathways affected by rhLIGHT. (B) Microarray analysis of rhLIGHT-treated cells.</p

Effects of Radotinib on the cell viability in AML cell lines.

<p>These data represent the means ± SEM. Significantly different from control, 0 μM (*);</p><p>***: <i>P</i> < 0.001;</p><p>*: <i>P</i> < 0.05.</p><p>Effects of Radotinib on the cell viability in AML cell lines.</p

Radotinib induces CD11b⁺Annexin V⁺ cells in AML cell lines.

<p>Cells were incubated with various concentrations of radotinib and/or ATRA for 72 h, harvested and immunostained with anti-human antibodies against CD11b and Annexin V, as described in the Methods. (A) NB4. (B) HL60. (C) Kasumi-1. (D) THP-1. (E) The CD11b⁺Annexin V⁺ cells in HL60. (F) Annexin V⁺ in the CD11b⁺ gated cells. (G) Schedule of differentiation induced cell death (plans A, B, C and D). (H) Cell death data by the respective plan. Data represent the mean ± SEM. Statistically significant differences from the DMSO-treated control (*) or ATRA treatment (#) are denoted as follows.*, #: <i>P</i> < 0.05; **, ##: <i>P</i> < 0.01; ***, ###: <i>P</i> < 0.001. Rd, radotinib; Das, dasatinib; ATRA, all-trans retinoic acid.</p